Result
€10.6m ▲ 295%
The result rose in 2025 from €2.7m to €10.6m.
VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Lifetime
18 annual accounts with figures on one time axis, 20 filings since 2006peak €52.6m (2025)
€52.6m▲ 19.4%
lowest -€5.2m (2022)
€10.6m▲ 295%
peak €172.4m (2025)
€172.4m▲ 7.0%
€151.3m▲ 2.3%
peak 928.4 FTE (2025)
928.4 FTE▲ 4.9%
Board50 names since 1995all names
14 directorsBart De Moor and 13 others
Documentsfilings and deeds
22-05-202670 days before the deadline
2025abbreviated format
Turnover from €44.0m to €52.6mResult from €2.7m to €10.6m3 directors appointed, 3 resignations, 4 reappointments 22-07Amendment of the articles 08-07Cash from €7.2m to €5.0m
Key points
from the 2025 annual accountsPayment terms
77 days to suppliers
VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY pays its suppliers 21 days later than in 2024. Customers pay 14 days later.
Filings
20 annual accounts since 2006
The last five annual accounts were filed 70 to 92 days before the end of the period.
At the same address
19 companies
Board
4 joined · 4 left
Board changed. Latest change 06-07-2026 · 14 in office.
Public contracts
46 awards
Public contracts awarded. To 32 suppliers, 2020 to 2026.
Checked score
96
Excellent
Financially stronger than 69% of all companies
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 16 companies (NACE 72, large).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025highest value
07-2025: < 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%● unchanged vs 07-2025highest value
09-2025: < 0.1%● unchanged vs 08-2025highest value
10-2025: < 0.1%● unchanged vs 09-2025highest value
11-2025: < 0.1%● unchanged vs 10-2025highest value
12-2025: < 0.1%● unchanged vs 11-2025highest value
01-2026: < 0.1%● unchanged vs 12-2025highest value
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026lowest value
07-2026: < 0.1%● unchanged vs 06-2026lowest value
08-2026: < 0.1%● unchanged vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 3.16, cash €5.0m
lowers risk
Legal form: non-profit association
Founded in 1995
Size: turnover €52.6m, 928.4 FTE, total assets €323.7m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (all companies). It does better than 69% of them on solvency, 48% on liquidity, 87% on profitability and 72% on growth.
The bankruptcy probability was computed on 06-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 513 companies had the same profile as VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY has now. Each dot stands for 2 companies, two years later.
96.1%
were still trading
3.1%
stopped another way
0.8%
went bankrupt
That fits the bankruptcy probability of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 513 companies, not a prediction for VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €5,250,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 3.16 (3.1 in 2024), above the usual 1.5. Short-term debt is 22.6% and cash 1.5% of total assets. 46.7% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-05-2026, 70 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
70 days early
2024
72 days early
2023
92 days early
2022
88 days early
2021
88 days early
2020
71 days early
2019
94 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 82 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 4 May (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
07-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
and 10 others
Shares in 3 companies, including Aelin Therapeutics and Confo Therapeutics
Board & ownershipRecent changes
4 directors appointed, 4 resignations, 1 statutory auditor reappointed
Appointments: Patrick Callaerts, Stefaan Vaes, Petra De Sutter and Katleen Verleysen · Resignations: Chris Van Geet, Gerard Govers, Katharina D'Herde and Koen Quaghebeur · Reappointment: EY (statutory auditor) · General meeting of 22-04-2026 · Gazette deed
3 directors appointed, 3 resignations, 4 reappointments
Reappointments: Luc Moens, Griet Nuytinck, Bart De Moor and Dieter Deforce · Appointments: Peter Schelkens, Maarten Weyn and Chris De Jonghe · Resignations: Hugo Thienpont, Ronny Blust and Gustaaf Van Reet · General meeting of 08-05-2025 · Gazette deed
Amendment of the articles
General meeting of 23-04-2025 · Gazette deed
Environmental permit granted
Nieuwbouw van bijgebouwen en niet overdekte lage constructie · Provincie Oost-Vlaanderen
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY Ghent | €52.6m | 19.9% | 53.3% | 928.4 |
| ABLYNX Ghent | €147.9m | -2.4% | 86.1% | 363.5 |
| KANEKA EUROGENTEC Seraing | €49.4m | -37.6% | 0.0% | 379.2 |
| BIOCARTIS Mechelen | €48.2m | -45.6% | 60.2% | 205.6 |
| Baxter R and D Europe Lessines | €58.8m | 6.0% | 57.9% | 178.3 |
| Legend Biotech Belgium Ghent | €285.9m | 6.6% | 44.2% | 846.9 |
| Ardena Holding Ghent | - | - | 96.7% | - |
Grey: the largest companies of the sector (research and development (NACE 72)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €53m and €417m, founded between 1979 and 2021.
Official details
Source: KBO- Status
- Active since 06-07-1995Normal situation
- Registered office
- 20 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 7 November 2026.
- Activity
- Research and development on biotechnologyNACE 72101
- Joint committee
- 335Services and support for business and the self-employed · annual accounts 2025
- Establishment units
- 2.138.473.7779052 Ghent, since 06-07-1995
- 2.138.473.8769052 Ghent, since 06-07-1995and 11 others
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- €190.2m▲ 12.5%
- €323.7m▲ 4.7%
- Employeeson 31-12-2025
- 1,084▲ 8.5%
- Filing
- Filed on 22-05-2026, 70 days before the end of the filing period
Companies linked to VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Subsidiaries and holdings
- AmphiStar0.51%
Insights on VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY has existed since 1995. Turnover grew from €20.7m in 2008 to €52.6m in 2025 and staff from 464.2 to 928.4 full-time equivalents.
Turnover has grown every year since 2022.
In July 2025, three directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
- What is the company number of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY?
- The company number of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY is 0456.343.923. The VAT number is the same number with BE in front: BE 0456.343.923.
- Where is VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY based?
- The registered office is at Suzanne Tassierstraat 1, 9052 Ghent.Company details
- What does VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY?
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY is a non-profit association (VZW).
- When was VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY founded?
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY was founded on 06-07-1995.
- Is VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY still active?
- Yes, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY is an active enterprise in the KBO register.
- How many employees does VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY have?
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY had an average of 928.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY fall under?
- In its 2025 annual accounts, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY states joint committee 335 (Services and support for business and the self-employed).
- What is the turnover of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY?
- The turnover of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY was €52.6m in financial year 2025, according to the filed annual accounts.
- Is VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY profitable?
- In financial year 2025, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY made a profit of €10.6m.
- Where can I find the annual accounts of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY?
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY due?
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.